Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression A SPECT Study
Por:
Sanches, RF, Osorio, FD, dos Santos, RG, Macedo, LRH, Maia-de-Oliveira, JP, Wichert-Ana, L, de Araujo, DB, Riba, J, Crippa, JAS, Hallak, JEC
Publicada:
1 feb 2016
Resumen:
Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in a bigger sample and to investigate its effects on regional cerebral blood flow. In an open-label trial conducted in an inpatient psychiatric unit, 17 patients with recurrent depression received an oral dose of ayahuasca (2.2 mL/kg) and were evaluated with the Hamilton Rating Scale for Depression, the Montgomery-angstrom sberg Depression Rating Scale, the Brief Psychiatric Rating Scale, the Young Mania Rating Scale, and the Clinician Administered Dissociative States Scale during acute ayahuasca effects and 1, 7, 14, and 21 days after drug intake. Blood perfusion was assessed eight hours after drug administration by means of single photon emission tomography. Ayahuasca administration was associated with increased psychoactivity (Clinician Administered Dissociative States Scale) and significant score decreases in depression-related scales (Hamilton Rating Scale for Depression, Montgomery-angstrom sberg Depression Rating Scale, Brief Psychiatric Rating Scale) from 80 minutes to day 21. Increased blood perfusion in the left nucleus accumbens, right insula and left subgenual area, brain regions implicated in the regulation of mood and emotions, were observed after ayahuasca intake. Ayahuasca was well tolerated. Vomiting was the only adverse effect recorded, being reported by 47% of the volunteers. Our results suggest that ayahuasca may have fast-acting and sustained antidepressive properties. These results should be replicated in randomized, double-blind, placebo-controlled trials.
Filiaciones:
Sanches, RF:
Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Ribeirao Preto, SP, Brazil
Hosp Santa Creu & Sant Pau, Ctr Invest Medicaments, Serv Farmacol Clin, Barcelona, Spain
Osorio, FD:
Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Ribeirao Preto, SP, Brazil
Natl Inst Sci & Technol, Translat Med, Ribeirao Preto, Brazil
dos Santos, RG:
Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Ribeirao Preto, SP, Brazil
Macedo, LRH:
Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Ribeirao Preto, SP, Brazil
Maia-de-Oliveira, JP:
Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Ribeirao Preto, SP, Brazil
Natl Inst Sci & Technol, Translat Med, Ribeirao Preto, Brazil
Univ Fed Rio Grande do Norte, Dept Clin Med, BR-59072970 Natal, RN, Brazil
Wichert-Ana, L:
Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Ribeirao Preto, SP, Brazil
de Araujo, DB:
Univ Fed Rio Grande do Norte, Onofre Lopes Univ Hosp, BR-59072970 Natal, RN, Brazil
Univ Fed Rio Grande do Norte, Inst Brain, BR-59072970 Natal, RN, Brazil
Riba, J:
Hosp Santa Creu & Sant Pau, Ctr Invest Medicaments, Serv Farmacol Clin, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Inst Recerca, Human Expt Neuropsychopharmacol, Barcelona, Spain
Univ Autonoma Barcelona, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain
CIBERSAM, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
Crippa, JAS:
Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Ribeirao Preto, SP, Brazil
Natl Inst Sci & Technol, Translat Med, Ribeirao Preto, Brazil
Hallak, JEC:
Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Ribeirao Preto, SP, Brazil
Natl Inst Sci & Technol, Translat Med, Ribeirao Preto, Brazil
Green Published
|